Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: A meta-analysis

Chinese Medical Journal

Volumn 122, Issue 14, 2009, Pages 1692-1698

  Shou, Zhang Fei ^a,b   Zhou, Qin ^b   Cai, Jie Ru ^b   Cheng, Jun ^b   He, Qiang ^a   Wu, Jian Yong ^a   Chen, Jiang Hua ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Alemtuzumab; Efficacy; Kidney transplantation; Meta analysis; Safety

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HUMAN; INFECTION RATE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; META ANALYSIS; METABOLIC DISORDER; PRIMARY TUMOR; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; XENOTRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COST-BENEFIT ANALYSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 70349546216     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.14.016     Document Type: Article

References (26)

1. Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi MA, Weimert NA, et al. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation 2009; 87: 408-414.
2. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-1399.
3. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
4. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs 2008; 68: 2113-2130.
5. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81: 1361-1367.
6. Ciancio G, Burke GW 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15-20.
7. Chen XD, Peng B, Gong RX, Wang L, Liao B, Li CL. Endoscopic thyroidectomy: an evidence-based research on feasibility, safety and clinical effectiveness. Chin Med J 2008; 121: 2088-2094.
8. Zhang S, Guo Y, Ma Y, Teng Y. Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J 2008; 121: 946-951.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
10. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
11. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Statist Med 1999; 18: 321-359.
12. Su YX, Zheng JW, Zheng GS, Liao GQ, Zhang ZY. Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis. Chin Med J 2008; 121: 1939-1944.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up. Transplant Proc 2008; 40: 2230-2233.
15. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 2008; 8: 1480-1485.
16. Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22: 200-210.
17. Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22: 41-49.
18. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509-1512.
19. Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola CB, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765-774.
20. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-465.
21. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782.
22. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88.
23. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S, et al. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81: 17-20.
24. Silveira FP, Marcos A, Kwak EJ, Husain S, Shapiro R, Thai N, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect 2006; 53: 241-247.
25. Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005; 37: 923-926.
26. Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, et al. Successful treatment of renal allograft rejection with a humanized anti-lymphocyte monoclonal antibody. Transplant Proc 1995; 27: 869-870.